Innovations in GLP-1 Receptor Agonist Therapy: Patient-Centered Strategies to Overcome Barriers and Reduce Cardiometabolic Risk in T2DM

Innovations in GLP-1 Receptor Agonist Therapy: Patient-Centered Strategies to Overcome Barriers and Reduce Cardiometabolic Risk in T2DM is organized by Integrity Continuing Education Inc.

Release date: September 27 2019
Expiration date: September 27, 2020

Accreditation:Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Overview:
To address the cardiovascular (CV) morbidity and mortality risks associated with Type 2 Diabetes Mellitus (T2DM), national guidelines now recommend the use of antidiabetic agents that have shown improvement in CV outcomes in clinical trials, including GLP-1 Receptor Agonists (RAs). Despite the benefits of these agents to patients with T2DM, recent data indicate a nationwide shortage in endocrinologists and geographically-related barriers to care may threaten the progress these agents have made in diabetes management. To meet the needs of patients with T2DM, the role of family practitioners (FPs) has expanded to fill the demand; however, FPs require education on the place of GLP-1 RAs in the management of diabetes, including pharmacokinetic/pharmacodynamic mechanisms, safety and efficacy data, Cardiovascular Outcome Trial (CVOT) outcomes, and patient satisfaction and adherence to fully embrace this evolving role. The extension of antidiabetic therapy beyond glycemic control has led to a paradigm shift in the management of T2DM. As a result, FPs must be prepared to take on a larger role in patient care. This activity will provide knowledge to address these educational needs among primarycare providers (PCPs), and application of this knowledge will improve outcomes for patients with T2DM.

Learning Objectives:
Upon completion of this educational activity, participants should be able to:
• Explain geographic trends in access to endocrinologists and define the critical role of PCPs in the management of T2DM
• Compare the underlying pathophysiological mechanisms and pharmacokinetic/pharmacodynamic profiles for currently available and emerging GLP-1 RA agents
• Evaluate updated guideline recommendations and the clinical trial data on the efficacy and safety of specific GLP-1 RAs, in addition to recent CVOT, patient satisfaction, and adherence data
• Identify common provider and patient-related barriers so that GLP-1 RAs can be introduced to more effectively control glucose, improve cardiometabolic risk factors, and increase patient satisfaction and adherence
• Describe the optimal use of GLP-1 RAs in the context of practice-based clinical scenarios